Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;41(1):133-140.
doi: 10.1097/MAO.0000000000002461.

Long-term Outcomes for the Treatment of Paragangliomas in the Upfront, Adjuvant, and Salvage Settings With Stereotactic Radiosurgery and Intensity-modulated Radiotherapy

Joshua L Anderson  1 , Mohamed H Khattab  2 , Chelsea Anderson  3 , Alexander D Sherry  1 , Guozhen Luo  2 , Nauman Manzoor  4 , Albert Attia  2 , James Netterville  4 , Anthony J Cmelak  2
Affiliations

Long-term Outcomes for the Treatment of Paragangliomas in the Upfront, Adjuvant, and Salvage Settings With Stereotactic Radiosurgery and Intensity-modulated Radiotherapy

Joshua L Anderson et al. Otol Neurotol. 2020 Jan.

Abstract

Objective: To analyze local control (LC) and toxicity rates between stereotactic radiosurgery (SRS) and intensity-modulated radiotherapy (IMRT) in relation to reported surgical rates in the treatment of paragangliomas (PG) in the upfront, adjuvant, and salvage settings, and to explore factors affecting tumor size reduction, toxicity rates, and symptom control.

Study design: Retrospective cohort analysis.

Setting: Tertiary referral center.

Patients and interventions: Thirty patients treated with either linear accelerator-based SRS or IMRT in the definitive, planned adjuvant, or unplanned salvage postsurgery settings.

Main outcome measures: Local control, toxicities, symptom control, tumor size reduction, and factors affecting each.

Results: Median follow-up was 4.16 years. LC rates were 100%. Acute grade >3 toxicity rate was 6.7%, 86.7% of tumors had a reduction in volume, and 76.7% of patients had improvement in at least one tumor-induced symptom by last follow-up. Larger tumor size at presentation and longer time to last follow-up were significantly associated with greater tumor size reduction on multivariate analysis.

Conclusions: SRS and IMRT are safe and effective treatment for PG with high efficacy and low morbidity rates in the upfront, planned adjuvant, and unplanned salvage settings.

PubMed Disclaimer

References

    1. Netterville JL, Sweeney AD, Wanna GB, Deep NL, Carlson ML. The Natural History of Jugular Paraganglioma. In: Contemporary Management of Jugular Paraganglioma; 2017.
    1. Al-Mefty O, Teixeira A. Complex tumors of the glomus jugulare: Criteria, treatment, and outcome. J Neurosurg 2002; 97:1356–1366.
    1. Forbes JA, Brock AA, Ghiassi M, Thompson RC, Haynes DS, Tsai BS. Jugulotympanic paragangliomas: 75 years of evolution in understanding. Neurosurg Focus 2012; 33: E13.
    1. Gilbo P, Morris CG, Amdur RJ, et al. Radiotherapy for benign head and neck paragangliomas: A 45-year experience. Cancer 2014; 120:3738–3743.
    1. Jansen JC, Van Den Berg R, Kuiper A, Van Der Mey AGL, Zwinderman AH, Cornelisse CJ. Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer 2000; 88:2811–2816.

LinkOut - more resources